Logo image of ALPRE.PA

PREDILIFE SA (ALPRE.PA) Stock Price, Quote, News and Overview

EPA:ALPRE - Euronext Paris - Matif - FR0010169920 - Common Stock - Currency: EUR

3.86  -0.08 (-2.03%)

ALPRE.PA Quote, Performance and Key Statistics

PREDILIFE SA

EPA:ALPRE (3/7/2025, 7:00:00 PM)

3.86

-0.08 (-2.03%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High8.5
52 Week Low3.22
Market Cap14.51M
Shares3.76M
Float1.00M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO12-21 2018-12-21


ALPRE.PA short term performance overview.The bars show the price performance of ALPRE.PA in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -5 -10 -15 -20

ALPRE.PA long term performance overview.The bars show the price performance of ALPRE.PA in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of ALPRE.PA is 3.86 EUR. In the past month the price increased by 1.58%. In the past year, price decreased by -8.96%.

PREDILIFE SA / ALPRE Daily stock chart

ALPRE.PA Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 21.07 346.68B
1ABBV.MI ABBVIE INC 20.82 342.48B
AMG.DE AMGEN INC 16.43 161.21B
1AMGN.MI AMGEN INC 15.84 160.89B
1GILD.MI GILEAD SCIENCES INC 25.67 135.84B
GIS.DE GILEAD SCIENCES INC 25.39 134.40B
VX1.DE VERTEX PHARMACEUTICALS INC 1667.04 115.58B
ARGX.BR ARGENX SE 253.61 33.75B
22UA.DE BIONTECH SE-ADR N/A 24.36B
IDP.DE BIOGEN INC 9.25 20.54B
1BIIB.MI BIOGEN INC 8.39 19.21B
0QF.DE MODERNA INC N/A 13.19B

About ALPRE.PA

Company Profile

ALPRE logo image Predilife SA operates as a medical technology company. The company is headquartered in Villejuif, Ile-De-France and currently employs 19 full-time employees. The company went IPO on 2018-12-21. The firm operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.

Company Info

PREDILIFE SA

Igr Campus Cancer 1 Batiment Maurice, 39 Rue Camille Desmoulins

Villejuif ILE-DE-FRANCE FR

Employees: 19

Company Website: https://www.predilife.com

Investor Relations: http://www.predilife.com/en/press-releases-and-publications/

Phone: 33142114211.0

PREDILIFE SA / ALPRE.PA FAQ

What is the stock price of PREDILIFE SA today?

The current stock price of ALPRE.PA is 3.86 EUR. The price decreased by -2.03% in the last trading session.


What is the ticker symbol for PREDILIFE SA stock?

The exchange symbol of PREDILIFE SA is ALPRE and it is listed on the Euronext Paris - Matif exchange.


On which exchange is ALPRE.PA stock listed?

ALPRE.PA stock is listed on the Euronext Paris - Matif exchange.


What is the price forecast or stock price prediction for PREDILIFE SA stock?

9 analysts have analysed ALPRE.PA and the average price target is 21.34 EUR. This implies a price increase of 452.81% is expected in the next year compared to the current price of 3.86. Check the PREDILIFE SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is PREDILIFE SA worth?

PREDILIFE SA (ALPRE.PA) has a market capitalization of 14.51M EUR. This makes ALPRE.PA a Nano Cap stock.


How many employees does PREDILIFE SA have?

PREDILIFE SA (ALPRE.PA) currently has 19 employees.


What are the support and resistance levels for PREDILIFE SA (ALPRE.PA) stock?

PREDILIFE SA (ALPRE.PA) has a support level at 3.56 and a resistance level at 3.9. Check the full technical report for a detailed analysis of ALPRE.PA support and resistance levels.


Is PREDILIFE SA (ALPRE.PA) expected to grow?

The Revenue of PREDILIFE SA (ALPRE.PA) is expected to grow by 115.63% in the next year. Check the estimates tab for more information on the ALPRE.PA EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy PREDILIFE SA (ALPRE.PA) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does PREDILIFE SA (ALPRE.PA) stock pay dividends?

ALPRE.PA does not pay a dividend.


What is the Price/Earnings (PE) ratio of PREDILIFE SA (ALPRE.PA)?

PREDILIFE SA (ALPRE.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.25).


ALPRE.PA Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to ALPRE.PA. When comparing the yearly performance of all stocks, ALPRE.PA is a bad performer in the overall market: 81.86% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

ALPRE.PA Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to ALPRE.PA. Both the profitability and financial health of ALPRE.PA have multiple concerns.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALPRE.PA Financial Highlights

Over the last trailing twelve months ALPRE.PA reported a non-GAAP Earnings per Share(EPS) of -1.25. The EPS decreased by -15.85% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -193.45%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%-20.75%
Sales Q2Q%-1.31%
EPS 1Y (TTM)-15.85%
Revenue 1Y (TTM)3.63%

ALPRE.PA Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 87% to ALPRE.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.

For the next year, analysts expect an EPS growth of -16.5% and a revenue growth 115.63% for ALPRE.PA


Ownership
Inst OwnersN/A
Ins Owners49.72%
Short Float %N/A
Short RatioN/A
Analysts
Analysts86.67
Price Target21.34 (452.85%)
EPS Next Y-16.5%
Revenue Next Year115.63%